FIND A CLINICAL TRIAL

CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 14-Apr-20
ARO-013
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 24-Mar-20
(Novartis) CLEE011O12301C / NATALEE / TRIO033
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 03-Mar-20
(Janssen) JNJ-74494550 AML1003
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 02-Mar-20
(ODI) ODO-TE-B202
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 27-Feb-20
(LHSC) ORATOR II
The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary surgical approach, to provide a high level of evidence to guide the selection of treatment options for a subsequent phase III trial
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 21-Feb-20
QBGJ098-301 PROOF
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose of the study is to evaluate the efficacy and safety of the investigational agent oral infigratinib vs standard of care chemotherapy (gemcitabine plus cisplatin) in first-line treatment of participants with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions/translocations. Subjects will be randomized 2:1 to receive infigratinib or gemcitabine plus cisplatin
CLICK HERE FOR DETAILS
CANCER TYPE: Neuroendocrine
LOCATION: Edmonton
OPEN DATE: 20-Feb-20
DX-GAL-001
A [68]Ga-HA-DOTATATE PET/CT or PET/MRI scan is a nuclear medicine test used to create pictures of the whole body that will show where somatostatin receptors are found, including on tumours. Somatostatin receptors are found on most neuroendocrine tumours (NETs), and some other types of tumours. Currently at the Cross Cancer Institute, most patients with suspected somatostatin positive tumours (e.g. NETs) have an In-111 Octreotide (Octreoscan™) scan. A scientific study has shown that a scan with a similar product ([68]Ga-DOTATATE) is more accurate than an Octreoscan™. This study will look at [68]Ga-HA-DOTATATE, a product virtually identical to [68]Ga-DOTATATE.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 11-Feb-20
(AZ) D9103C00001/PACIFIC-4/RTOG-3515
This is a phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following standard of care stereotactic body radiotherapy in patients with unresected clinical stage I/II lymph node-negative (T1 to T3N0M0) non-small cell lung cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 11-Feb-20
(CCTG) OVC.2 / NRG-GY005
Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 SPVd, Arm 6 SKd, Arm 8 SNd, Arm 9 SPEd) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 11-Feb-20
CA209-722
The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 07-Feb-20
CA209-73M
The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 05-Feb-20
GSK 209229
The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC). This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) >=1 R/M HNSCC. Approximately 600 participants will be enrolled in the study and will have a follow-up until death.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 31-Jan-20
TED14856
A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 31-Jan-20
(CCTG) MAC.24 / S1418 / BR006 / MK-3475-242
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 02-Jan-20
GSK 204653
A phase I, open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin’s lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 19-Dec-19
(Sanofi) ACT16105
A randomized phase II trial of SAR439859, a new SERD compound, versus fulvestrant in patients with hormone-receptor positive, HER2 negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 17-Dec-19
(Roche) CO41012 / IPATunity150
The open-label Phase Ib portion of this study will evaluate the safety and pharmacokinetics of ipatasertib in combination with palbociclib and fulvestrant to identify a dose of ipatasertib that can be combined with palbociclib and fulvestrant in the Phase III portion. The randomized Phase III portion of this study will evaluate the efficacy, safety, and patient-reported outcome (PRO) objectives of ipatasertib + palbociclib + fulvestrant compared with placebo + palbociclib + fulvestrant in patients with HR+ HER2-, locally advanced unresectable or metastatic breast cancer who had relapsed during adjuvant endocrine therapy or progressed during the initial 12 months of first-line endocrine therapy in locally advanced unresectable or metastatic breast cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 06-Dec-19
AbbVie M14-239
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 06-Dec-19
(CCTG) MAC.23 / Alliance A221505 / RT CHARM
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 04-Dec-19
TPX-0005-01
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 27-Nov-19
CA 030 001
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 26-Nov-19
AALL1731
Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 20-Nov-19
(Daiichi Sankyo) DS8201-A-U303
A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 11-Nov-19
CA209 8HW
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 07-Nov-19
(Merck) MK-7339-001 / ENGOT-ov43 /KEYLYNK-001 / 194619
Cannot be removed by an operation
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 07-Nov-19
(Pfizer) C3441021 / TALAPRO-2
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 05-Nov-19
CACZ885T2301
The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Calgary
OPEN DATE: 31-Oct-19
(Incyte) INCMGA 0012-201/PODIUM 201
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 30-Oct-19
D9108C00001 (COAST)
The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Edmonton
OPEN DATE: 30-Oct-19
KCP-330-024
Patients with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized to selinexor or placebo until disease progression.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 22-Oct-19
R1979-ONC-162
An open-label study to assess the anti-tumor activity and Safety of regn1979, an anti-cd20 x anti-cd3 bispecific Antibody, in patients with relapsed or refractory Follicular lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Multiple Tumour Group
LOCATION: Calgary
OPEN DATE: 22-Oct-19
(Amgen) 20180143
To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 21-Oct-19
CA 209 8FC
A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 09-Oct-19
(Merck) MK-3475-866 / KEYNOTE-866
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 04-Oct-19
(Exelixis) Cosmic 313
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 676 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio (~338 per treatment arm) at approximately 180 sites.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 02-Oct-19
20170543
Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant solid tumors. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) within investigated subject population groups.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 27-Sep-19
D933QC00001
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 18-Sep-19
(CCTG) REC.4 / EA8143
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
CLICK HERE FOR DETAILS
CANCER TYPE: Cutaneous
LOCATION: Calgary
OPEN DATE: 13-Sep-19
(Sanofi) TCD14678
A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult patients with advanced solid tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 12-Sep-19
1948-CL-0101
Targeting an Immune Modulatory Receptor, in subjects with Advanced Solid Tumors (i.e., non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC), ovarian cancer, melanoma and breast cancer, squamous cell carcinoma of the head and neck (SCCHN), etc.)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 10-Sep-19
(Janssen) CR108598 / 54767414MMY2065
The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab intravenous (Dara-IV) to evaluate daratumumab retreatment
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 09-Sep-19
(AHS) Bone Turnover
The primary study objective is to measure relief of dysphagia, defined as improvement of at least one point on the Mellow dysphagia scale. This will be measured at 9 weeks after the start of RT and must be maintained at the next review 4 weeks thereafter (week 13). Secondary study objectives include dysphagia progression-free survival, time to achieving any response in dysphagia after treatment, number of patients receiving secondary treatment, utility assessments and quality of life differences. Other objectives inlude examining acute and late toxicity and collecting serum for studies of tumor response and toxicity. All eligible and enrolled patients with non-curable cancer of the esophagus will receive external beam radiaito therapy of 30Gy/10 fractions over two weeks and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on days 1, 8.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Edmonton
OPEN DATE: 06-Sep-19
MK 7902-001
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS).
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 04-Sep-19
(Clovis) CO-338-063 / TRITON 3
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 28-Aug-19
DHA-WIN
Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 15-Aug-19
AGCT1532
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 06-Aug-19
MK7339-010
Phase 3, Randomized, Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy
CLICK HERE FOR DETAILS
CANCER TYPE: Sarcoma
LOCATION: Edmonton
OPEN DATE: 01-Aug-19
DCC-2618-03-002
This study is a global, open-label Phase 2a/2b study to determine the efficacy and safety of KRT-232. In Part A of the study, patients will be randomly assigned to 5 arms with 2 different doses and 3 different dosing schedules of KRT 232. In Part B of the study, patients will be randomized either to treatment with KRT-232 administered at the recommended dose and schedule from Part A or to treatment with ruxolitinib.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 31-Jul-19
(EXELIXIS) XL184-312 / COSMIC-312
Has spread to other parts of the body
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 25-Jul-19
SCH ACCL1333 BMS CV185-155
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 03-Jul-19
MK3475-630
This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 03-Jul-19
(Celgene) BB2121-MM-003
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 02-Jul-19
DREAM
Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 02-Jul-19
MK 3475-689
This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves major pathological response and event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Calgary
OPEN DATE: 28-Jun-19
(Exelixis) XL184-311/COSMIC-311
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 28-Jun-19
(GSK) 205207 DREAMM 4
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 27-Jun-19
BI1381-0009
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 21-Jun-19
MCRN007
A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 17-Jun-19
MK-7902-007
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Non-small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 05-Jun-19
(Clovis) CO-338-087 / GOG-3020 / ENGOT-ov45/NCRI/ATHENA
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 05-Jun-19
Headstart
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 04-Jun-19
(Kartos Therapeurtics, Inc.) KRT-232-102
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with phlebotomy-dependent polycythemia vera (PV). Inhibition of MDM2 in PV is a new mechanism of action in PV. In Part A, patients must be resistant or intolerant to hydroxyurea or have undergone treatment with interferon. In Part B, patients must be resistant or intolerant to hydroxyurea.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 31-May-19
(AstraZeneca) D933SC00001 / NILE
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 31-May-19
MK 3475-756
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER+/HER2–) Breast Cancer (KEYNOTE-756)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 31-May-19
(Kartos Therapeutics Inc.) KRT-232-101
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study is a global, open-label Phase 2 study to determine the efficacy and safety of KRT-232 in patients with primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF who have failed previous treatment with JAK inhibitor (Part A), or Ruxolitinib (Part B). In Part A of the study, patients will be randomly assigned to 2 different doses and 2 different dosing schedules of KRT-232. In Part B of the study, patients will be treated at the recommended dose and schedule from Part A.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 23-May-19
CC-95251-ST-001
Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 14-May-19
Pfizer B1761031
This is a single‑arm, open‑label, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a single‑agent monotherapy in adult and pediatric patients with relapsed or refractory CD33‑positive AML.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 14-May-19
(Princess Margaret Cancer Centre) 18-5353 / VALUE
Current guidelines in non-small cell lung cancer recommend genomic assessment for mutations in EGFR and BRAF, gene rearrangements in ALK and ROS1, and resistance mutations such as T790M upon progression during EGFR inhibitor therapy. However, obtaining sufficient tumour tissue to test for these molecular alterations, as well as those with emerging targeted therapies, is challenging in lung cancer. A promising method to improve molecular diagnostic testing in lung and other cancers is the use of circulating cell-free DNA (cfDNA) obtained from blood samples or liquid biopsies. This multi-centre prospective study will compare blood-based profiling (using the GUARDANT360 assay) to standard of care tissue-based profiling within the Canadian system.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 14-May-19
(Roche) BO40747
This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin + cyclophosphamide) followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 10-May-19
(AstraZeneca) D5084C00007 / SAVANNAH
A Phase II, Single Arm Study Assessing Efficacy of Osimertinib With Savolitinib in Patients With EGFRm+ MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study)
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 10-May-19
(Celgene) ACE-536-MDS-002 / COMMANDS
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 08-May-19
(Acerta Pharma BV) ACE-CL-311 / D8221C00001
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 08-May-19
(CCTG) CRC.8/ EA2165
This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Calgary
OPEN DATE: 07-May-19
(Ayala) AL-ACC-01 / ACCURACY
A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 03-May-19
SGNTV-001
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 02-May-19
GSK205801
Participants' cancer:
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 02-May-19
ALK 4230-A101
To better understand the safety and tolerability of ALKS 4230 in humans
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 22-Apr-19
(Astellas) 8951-CL-0302 / GLOW
The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
CLICK HERE FOR DETAILS
CANCER TYPE: Sarcoma
LOCATION: Edmonton
OPEN DATE: 05-Apr-19
KCP-330-020
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 334 total patients will be randomized to study treatment (selinexor or placebo).
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 05-Apr-19
IIT-UNSCARRed
Participants must have HER2-low breast cancer that has been treated before.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Edmonton
OPEN DATE: 04-Apr-19
3000-03-005
A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV NonMucinous Epithelial Ovarian Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 01-Apr-19
(CCTG) OV.25 / STICs AND STONEs
A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs)
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 19-Mar-19
OZM-088
The study is an open label, paucicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 04-Mar-19
NP40126
A Phase 1B Study Evaluating RO7082859 in Combination with Rituximab (R) or Obinutuzumab (G) plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants with Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants with Untreated Diffuse Large B Cell Lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 28-Feb-19
(Daiichi Sankyo Inc.) DS8201-A-U302
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 27-Feb-19
ACT15377
A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 27-Feb-19
CA 209 848
The purpose of this study is to determine whether nivolumab plus ipilimumab or nivolumab alone is effective and safe in the treatment of solid tumors with High Tumor Mutational Burden (TMB-H)
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 26-Feb-19
CA 045 001
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 25-Feb-19
CA027-002
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab in patients with advanced cancers.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 20-Feb-19
8374-CL-0101
A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 19-Feb-19
SYD985
The purpose of this study is to demonstrate that SYD985 [(vic-)trastuzumab duocarmazine] is superior to physician's choice in prolonging progression free survival.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 06-Feb-19
D933RC00001
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 31-Jan-19
CA 209 9DX
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 29-Jan-19
AHEP1531
This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone.
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 15-Jan-19
MK3475-716
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for up to 17 cycles. Participants who receive placebo or who stop treatment after receiving 17 cycles of pembrolizumab in Part 1, do not experience disease recurrence within 6 months of completing pembrolizumab in Part 1, and do not stop treatment with pembrolizumab for disease recurrence or intolerability, may be eligible to receive up to 35 additional cycles of pembrolizumab in Part 2 in an open-label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 11-Jan-19
PanGen
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
CLICK HERE FOR DETAILS
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 21-Dec-18
FINE ART
Randomized Trial of Unilateral vs Bilateral Neck Irradiation in Head and Neck Cancer Patients Treated with Primary Surgery
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 07-Dec-18
CCTG MAC 19
This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x rays or protons to kill tumor cells. It is not yet known if radiation therapy works better alone or with lymph node dissection in treating patients with breast cancer previously treated with chemotherapy and surgery.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 27-Nov-18
SPI-POZ-202
This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts 5, 6 and 7).
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 27-Nov-18
(CCTG) MA.39 / TAILOR RT
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 21-Nov-18
(AMGEN) 20150161
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 08-Nov-18
8951- CL-0301
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 07-Nov-18
CCTG HN.9
Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 22-Oct-18
(Sunnybrook Research Institute) 0891 / SPIREL
This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two months with low dose metronomic oral cyclophosphamide (50 mg BID) for one year or until disease progression, whichever occurs first. Pembrolizumab 200 mg will be administered every 3 weeks for up to one year or until disease progression, whichever occurs first.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 16-Oct-18
BGB-3111-212
The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 26-Sep-18
MOR208C204
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
CLICK HERE FOR DETAILS
CANCER TYPE: Neuro
LOCATION: Calgary
OPEN DATE: 25-Sep-18
(CCTG) CE.7
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy (WBRT) is when radiation therapy is given to the whole brain. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 24-Sep-18
NRG-GU005 / HYPORT
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 18-Sep-18
IIT Imatinib-CCI-PH1-01
A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodum Iodide Symporter Function and Sensitivity to Radioiodin Treatment in Metastatic Thyroid Cancer Patients
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 17-Sep-18
CA 018-003
The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 05-Sep-18
(ImmunoVaccine) ONC-DPX-Survivac-06
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 30-Aug-18
CPI-0610
Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 17-Aug-18
Bayer 18594
We hypothesize that the use of rRT will be feasible (physicians will be willing to offer rRT, patients will be willing to undergo rRT, and courses of rRT will be able to completed in a timely manner [per the usual schedule of 5 days a week]), safe (patients will experience few, if any, grade 3 [severe] or grade 4 [life-threatening] toxicities), and effective in prolonging life (that we will be able to increase the median survival after progression from 3 months [offering symptom control only] to 6 months [offering rRT and symptom control] compared to an historic cohort).
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 31-Jul-18
(AHS) MK3475-418 P-CUP
Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis carcinoma of unknown primary site Trial Type: Single arm phase 2 Type of control: Not applicable Route of administration: Intravenous Trial Blinding: Not applicable Treatment Groups: 1) Pembrolizumab 200 mg IV every 3 weeks for up to 24 months. Total Number of trial subjects:25 Estimated enrollment period: 24 months Estimated duration of trial: 48 months Duration of Participation: 24 months
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 30-Jul-18
(CUOG) PRIME
A Randomized Phase 3 Trial of Metformin in Patient Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 30-Jul-18
Astex 727-02 MDS
Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, subjects will continue to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the subject discontinues treatment or withdraws from the study.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 14-Jun-18
KEYNOTE-651
RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 24-May-18
(Celgene) CC-92480-MM-001
This is an open-label, multi-center, international, Phase 1 study to assess the safety, PK/PD and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with RRMM.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 08-May-18
(AstraZeneca) XD5336C00001 234970 / VIOLETTE
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 01-May-18
CO40016 (IPATunity)
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) breast adenocarcinoma who are not suitable for endocrine therapy.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 26-Apr-18
CCTG IND 234
The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 20-Apr-18
ALTE16C1
This research trial studies saliva, semen, and blood samples to determine effects of chemotherapy on fertility in osteosarcoma survivors. Study biospecimen samples from osteosarcoma survivors in the laboratory may help doctors learn whether chemotherapy causes fertility problems and to learn more about the long term effects.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 11-Apr-18
CCTG MAC.21
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 10-Apr-18
CCTG IND.223
The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib. The researchers doing this study are also interested in looking for markers that may help predict which patients are most likely to be helped by palbociclib and to see how the cancer cells respond to palbociclib.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 04-Apr-18
(Basilea) DZB-CS-301
This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene mutations or amplifications (based on NGS testing performed or commissioned by the respective study center) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib capsules.
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 20-Mar-18
AZ D6185C00001
This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 18-Mar-18
CV202-103
This is a Phase 1b/2, open-label, 2-part, multicenter trial to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BMS-813160 in combination with either FOLFIRI, gemcitabine (Gem)/nab-paclitaxel (ABRAXANE), or nivolumab in participants with advanced CRC or pancreatic cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 08-Mar-18
APEC14B1
This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 08-Mar-18
(Horizon Health Network) The M4 Study
The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment. The main hypothesis is that these tests will allow clinicians to better diagnose and manage multiple myeloma, improving patients' quality of life overall.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 28-Feb-18
(Abbvie) M15-654
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 2 distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd). Each Part will be initiated with a dose-escalation phase in which increasing doses of venetoclax will be given with fixed doses of daratumumab and dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone (Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion phase
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 23-Feb-18
ALTE15N2
This research trial studies late effects after treatment in patients with previously diagnosed high-risk neuroblastoma. Studying late effects after treatment may help to decide which treatments for high-risk neuroblastoma are better tolerated with less side effects over time.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 09-Feb-18
MK 4280-001-2003
This is a nonrandomized, multisite, open-label, dose-escalation study of MK-4280 monotherapy (Part A, Arm 1) and MK-4280 in combination with pembrolizumab (Part A, Arm 2) followed by a dose confirmation and efficacy evaluation of MK-4280 in combination with pembrolizumab (Part B) in subjects with a histologically or cytologically confirmed diagnosis of advanced solid tumors.
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Edmonton
OPEN DATE: 07-Feb-18
LATENT
A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab with Valproic Acid for the Treatment of Virus-associated Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 18-Jan-18
Debio1143-NSCLC-105
A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after platinum-based therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 15-Jan-18
(AbbVie) P16-489 DEVOTE
Post-marketing observational study (PMOS) to describe the management and the use of healthcare resources in patients with chronic lymphocytic leukemia (CLL) initiating venetoclax in routine clinical practice (DEVOTE)
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 08-Jan-18
TINI
The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease the number of leukemia cells, but it could also cause additional side effects. Bortezomib and vorinostat have been approved by the US Food and Drug Administration (FDA) to treat other cancers in adults, but they have not been approved for treating children with leukemia. With this research, we plan to meet the following goals:
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Edmonton
OPEN DATE: 20-Dec-17
BO29554
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 29-Nov-17
(AstraZeneca) D5160C00006 / TATTON
This is a Phase Ib, open-label, multi-arm, multicentre study of AZD9291 administered orally in combination with AZD6094 or selumetinib (or MEDI4736 [no longer being evaluated under this amendment]) in patients with EGFRm+ NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional anti-cancer regimens). The study design allows escalation or de-escalation of AZD6094 or selumetinib doses with intensive safety monitoring to ensure the safety of the patients.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 24-Nov-17
Astellas 2215-CL-0201 LaceWing
This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some patients with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster.
CLICK HERE FOR DETAILS
CANCER TYPE: Neuro
LOCATION: Calgary
OPEN DATE: 13-Nov-17
(Orbus) OT-15-001 / STELLAR
The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.
CLICK HERE FOR DETAILS
CANCER TYPE: Multiple Tumour Group
LOCATION: Calgary
OPEN DATE: 17-Oct-17
(Astex) ASTX660-01
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 26-Sep-17
(Amgen) 20160275 / CANDOR
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 26-Sep-17
H3B-6527-G000-101
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
CLICK HERE FOR DETAILS
CANCER TYPE: Multiple Tumour Group
LOCATION: Edmonton
OPEN DATE: 17-Jul-17
ESPS-001
The main purpose of this two-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 10-Jul-17
(Tesaro) 4010-01-001 / GARNET
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 22-Jun-17
ACE-LY-308
This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 14-Jun-17
(SHSC) OZM-065
A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 12-Jun-17
(UHN) OZM-058
This is a study that will look at the effects and how useful investigational drug olaparib is as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment) prior to surgery in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 08-Jun-17
MDV3800-13
A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 19-May-17
MK 3475-365-0102
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will be four cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, and cohort D will receive pembrolizumab + abiraterone + prednisone. Outcome measures will be assessed individually for each cohort.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 15-Apr-17
ReRAD
A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
CLICK HERE FOR DETAILS
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 21-Mar-17
STOP-NSCLC
A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive metastatic cancers. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 17-Mar-17
(CCTG) IND.227
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 16-Mar-17
OZM-063
This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants will be randomized to Arm A or Arm B. Arm A includes 68 weeks of single agent Vinblastine administered once weekly IV. Arm B includes 68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks. Randomization will take place at the time of registration taking into account NF1 and BRAF-KIAA1549-fusion status.
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 16-Feb-17
CCTG ME 13
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.
CLICK HERE FOR DETAILS
CANCER TYPE: Other
LOCATION: Edmonton
OPEN DATE: 23-Dec-16
ACE Study
The primary purpose of this proposed 5-year hybrid effectiveness and implementation study is to evaluate the relative benefit from, and implementation of an Alberta wide clinic-to-community-based cancer and exercise model of care - the Alberta Cancer Exercise (ACE) Program. The investigators hypothesize that the strategy will improve the physical well-being and QoL of survivors (on and off cancer treatment) while preventing the development of secondary cancers.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 17-Nov-16
Stemline SL-401-0314
This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or myelofibrosis (MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive chemotherapy; and one enrolling treatment-naive patients with CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort will enroll patients who are resistant/refractory or intolerant to approved JAK therapy (JAK1/JAK2 or JAK2).
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 17-Nov-16
(Novartis) CRAD001YCA09 TreatER+ight
For patients with AML who cannot receive standard chemotherapy, azacitidine (also known as Vidaza®) is a current standard of care treatment option in the United States. This clinical study is testing an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib works by stopping the leukemia cells from making the FLT3 protein. This can help stop the leukemia cells from growing faster.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 11-Oct-16
POE16-01
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Neuro
LOCATION: Calgary
OPEN DATE: 22-Sep-16
(CCTG) CEC.6
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 26-Jul-16
NCIC HE.1
The purpose of this study is to see whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting standard BSC alone.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 21-Jul-16
CPI-444-001
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 29-Jun-16
IIT-RATIO
This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
CLICK HERE FOR DETAILS
CANCER TYPE: Melanoma
LOCATION: Edmonton
OPEN DATE: 31-May-16
Amgen 20120139
Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 23-May-16
GH29914
The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible for cytotoxic therapy.
CLICK HERE FOR DETAILS
CANCER TYPE: Phase I
LOCATION: Edmonton
OPEN DATE: 12-May-16
CA 017 003
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 15-Apr-16
(AHS) APBI 27/5 / ACCEL
Accelerated Partial Breast Irradiation Using Five Daily Fractions: A Single Arm, Phase II, Prospective Cohort Study to Examine Cosmetic Outcomes and Toxicity (The ACCEL Trial)
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 07-Apr-16
SJMB12
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 04-Apr-16
NRG - BR002
This is a phase IIR/III, randomized, multicenter trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for patients with newly oligometastatic breast cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Head and Neck
LOCATION: Calgary
OPEN DATE: 29-Feb-16
NRG - HN001
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 02-Feb-16
NRG - BR003
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Multiple Tumour Group
LOCATION: Calgary
OPEN DATE: 14-Oct-15
RTOG 1112
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send the radiation dose directly to the tumor and cause less damage to normal tissue. Giving sorafenib tosylate together with stereotactic body radiation therapy may kill more tumor cells.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 11-Sep-15
(Karyopharm) KCP-330-017 / STOMP
This study will independently assess the efficacy and safety of 8 combination therapies in 9 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are:
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 16-Jul-15
POE14-01
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 05-May-15
(CCTG) LY.17
The purpose of this study is to find out what effects new combinations of treatment will have this disease. In this clinical trial, the study treatment options currently are ibrutinib plus R-GDP, or R-GDP alone.
CLICK HERE FOR DETAILS
CANCER TYPE: Blood and Marrow Transplant
LOCATION: Calgary
OPEN DATE: 14-Apr-15
(AHS) HDM-Gem-HDT-ASCT-Shafey GEMHDM2014
Infusional Gemcitabine and High-dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 19-Mar-15
(CCTG) BR.31
Whether or not there are chromosomal abnormalities in the tumor, and if present, what type (also called cytogenetics analysis)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 04-Dec-14
RTOG 1304
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 28-Jul-14
ANBL1232
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment
CLICK HERE FOR DETAILS
CANCER TYPE: Neuro
LOCATION: Calgary
OPEN DATE: 26-May-14
(RI MUHC) McG 1132
The purpose of this study is to determine whether a combination of Sunitinib, Temozolomide and Radiation Therapy would be effective in the treatment of newly diagnosed Glioblastoma patients harboring tumors with unmethylated MGMT promoter. Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
CLICK HERE FOR DETAILS
CANCER TYPE: Neuroendocrine
LOCATION: Edmonton
OPEN DATE: 29-Apr-14
TX-LUT-001
Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to be a safe and effective palliative therapy, and has been widely used by research groups in Europe. A brand of Lu-DOTA-TATE (Lutathera(R)) is approved for the treatment of gastroenteropancreatic NETs in Europe, the U.S., and more recently in Canada. While Lutathera(R) is approved in Canada, it is not available in Alberta yet. This study is being done to provide access to Lu-DOTA-TATE treatment for patients with somatostatin receptor positive tumours. Lu-DOTA-TATE has been used at the Cross Cancer Institute to treat more than 300 patients with NETs since August, 2010. Our Lu-DOTA-TATE treatment was initially given under Health Canada's Special Access Programme (SAP), with each individual treatment requiring separate approval. In 2014, Health Canada requested we conduct a clinical trial with Lu-DOTA-TATE instead.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 05-Aug-13
ALTE11C2
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 15-Jul-10
(CCTG) CO.21 / CHALLENGE
This randomized phase III trial is studying a physical activity program given together with health education materials to see how well it works compared with giving health education materials alone for patients who have undergone treatment for high-risk stage II or stage III colon cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 15-Sep-08
ALTE07C1
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 21-May-04
ALTE03N1
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Calgary
OPEN DATE: 29-Mar-01
ANBL00B1
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
CLICK HERE FOR DETAILS